Immunic

Immunic, Inc. is a clinical biopharmaceutical company with a range of selective oral immunotherapies designed to treat chronic inflammatory and autoimmune diseases, including relapsing multiple sclerosis, ulcerative colitis, Crohn's disease, and psoriasis. The company is developing three small molecule products: the leading development program IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the DHODH enzyme and has host-based antiviral effects; IMU-935 is an inverse agonist of RORγt; IMU-856 aims to restore intestinal barrier function.